OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Conditions:   Exocrine Pancreatic Insufficiency (EPI);   Cystic Fibrosis (CF) Interventions:   Drug: MS1819-SD;   Drug: Porcine PERT Sponsor:   AzurRx BioPharma, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials